PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of utreloxastat could achieve a two-point difference on ALSFRS, an instrument for evaluating the functional status of ALS patients. The drug candidate fell short of that bar.
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
Philadelphia dad Eric Brunner was diagnosed with amyotrophic lateral sclerosis, the fatal disease known as ALS. He wants to ...
A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...
Live Science on MSN1d
'Exercise juice' released by muscles helps nerves grow, study findsIn a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including ...
Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...
Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...
There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...
A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback